The site of pathological changes among the 37 cases varied: 19 (51.4%) in ileocecal area, 11(29.7%) in ascending colon, 3(8.1%) in transverse colon, 3(8.1%) in descending colon, 1(2.7%) in sigmoid colon. The pathological examination showed non-Hodgkin

lymphoma in all patients. The tumor might originate from the following organisms: B cell (n = 29,78.4%), T cell (n = 8,21.6%). MK-8669 The coincidence rate of endoscopic biopsy with pathology of resected specimen was 40.0 percent (12/30). Surgeries followed by chemo-radiotherapy were major treatment. The sum 5 year survival rate was 61.2% in 28 cases followed up. Conclusion: primary colon malignant lymphoma is characterized by multiple clinical manifestations. Abdominal pain and abdominal mass, fever, loss of weight, and change in bowel movements constituted the clinical aspects of primary colon malignant lymphoma. Radical surgery combined with chemotherapy is the main therapy against primary colon malignant lymphoma. Key Word(s): 1. colon lymphoma; 2. diagnosis; 3. treatment; Presenting Author: FENG QING-QING Corresponding Author: FENG QING-QING Affiliations: Nanchang University Objective: Unlike normal cells, glycolysis is enhanced in cancer cells. Pyruvate dehydrogenase kinase-I (PDK-I) catalyze cell glycolysis. In this study, the expressions of PDK-I and Ki-67 nuclear antigen (Ki-67) were investigated in colon cancer in order to reveal their

clinical significance. Methods: The protein expressions of PDK-I and Ki-67 in MCE 41 patients (≤40 years) with colon cancer and 36 patients GSI-IX chemical structure (> 40 years),

were detected by immunohistochemical technique with retrospective comparison. Results: The positive expression rates of PDK-I were 80.5% (33/41) and 66.7% (24/36) in young group and older group respectively. Moreover, the Ki-67 proliferation indexes of both groups were (56.2 ± 2.3)% and (45.4 ± 3.1)% respectively. Compared the young group with the older group, there were significant differences in the two positive expressions (both, P < 0.01). Moreover, compared these positive expressions of PDK-I and Ki-67 with those negative expressions in the young colon cancer patients, there were significant differences in cancer’s differentiation and stage (both, P < 0.01). The positive expression of PDK-I was consistent with the positive expressions of Ki-67 in young patients with colon cancer. Conclusion: The positive protein expressions of PDK-I may be malignant biomarkers. Key Word(s): 1. colon cancer; 2. PDK-I; 3. glycolysis; Presenting Author: JIN DAI Additional Authors: JIE CHEN, MINHU CHEN Corresponding Author: JIN DAI Affiliations: The First Affiliated Hospital of Sun Yat-Sen University Objective: Gastrokine-2 (GKN2) is a secretory protein which is expressed in gastric epithelial cells and may be used as candidate gene of gastric cancer inhibitory gene. It is reported that trefoil factor 1 (TFF1) and trefoil factor 2 (TFF2) can respectively bind GKN2 together.